Pharmaceutical compositions and their use for the treatment of autoimmune disorders
AssigneeUniversite Grenoble Alpes
InventorsBertrand Huard, Patrice Lalive
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversite Grenoble Alpes
InventorsBertrand Huard, Patrice Lalive
Estimating the term…
A pharmaceutical composition in which the active substance includes or is: (i) a protein including the sequence SEQ ID NO: 1, representing the APRIL protein, (ii) any derived protein, which is derived from protein of sequence SEQ ID NO: 1 by substitution, removal or addition of one or more amino-acids, provided it allows the binding of the derived protein to an astrocyte and/or CSPG, (iii) any homologous protein, the sequence of which has a percentage of identity of at least approximately 70%, and in particular 85% with the sequence SEQ ID NO: 1, provided it allows the binding of the homologous protein to an astrocyte and/or CSPG, or (iv) any fragment of the protein of sequence SEQ ID NO: 1, provided it allows the binding of the fragment to an astrocyte and/or CSPG. The active substance is in association with an acceptable pharmaceutical vehicle.
A method of interfering with an antiregenerative process mediated by Chondroitin Sulfate ProteoGlycans (CSPG) comprising administering to a subject in need thereof a composition comprising an active substance which comprises or consists of:
A method for treating multiple sclerosis or autoimmune encephalitis, said method comprising administering to a subject in need thereof an effective amount of a composition comprising an active substance which comprises or consists of:
Dependencies are inferred from the claim text.